Oceanographers study the impact of toxic ash from the Los Angeles wildfires on marine life
Los Angeles — A research ship from the San Diego-based Scripps Institute of Oceanography goes out every three months along the Southern California coastline.
Recently, the ship was traveling the coast collecting plankton samples, small organisms that many larger fish live on. But this trip was anything but ordinary.
"This is something I've never experienced before, and I don't know anybody else that has," Scripps Institute scientist Dr. Rasmus Swalethorp told CBS News.
What the researchers experienced, by total coincidence, was pulling up to Los Angeles in January as the deadly and devastating Palisades and Eaton fires were burning thousands of homes, incinerating plastic, paint, asbestos and car batteries. The fires released a cloud of toxic ash that settled over the ocean for about 100 miles.
Crew members put on masks to protect against the smoke as black ash settled on the ship, while the plankton they collected was also swimming in ash.
"All the organisms that are going to live down on the seabed, they're certainly going to be exposed to this, potentially transporting whatever is in that ash further up the food chain," Swalethorp said.
Scientists with the Scripps Institute have been collecting California ocean samples for 75 years. The new ash-laden samples will be added to this vast archive.
"We know what the fish are like under normal circumstances, but the scientific opportunity here is to look at the condition of the fish when they're exposed to all the ash," said Andrew Thompson, a scientist with the National Oceanic and Atmospheric Administration.
Commercial and recreational fishing in California brings in about $1 billion a year and supports 193,000 full and part-time jobs, according to numbers from the NOAA. While it could take years to know how, or if, these toxins impact fish, both fishermen and restaurants say knowing the answer is important.
"The damage that these fires has caused is like woven so deeply into the fabric of our food systems that it's something that you know, it should be just an absolute red flag for anyone involved…a red flag for change," said Michael Cimarusti, a chef at the L.A. seafood restaurant Providence. "Like, what can be done to ensure that these kinds of fires, like, don't happen again."
Swalethorp says monitoring how ocean life responds will continue for years.
"We are also going to be looking for chromium, for mercury," Swalethorp said. "…Things we don't want in the ocean."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
New Treatment May Cure Severe Type 1 Diabetes, Study Finds
A dozen volunteers with severe type 1 diabetes showed clear improvements in their condition 12 months after receiving a revolutionary stem cell treatment, with all but two dropping their insulin therapy altogether. The phase 1/phase 2 clinical trial results provide hope for the 8.4 million people around the world with type 1 diabetes; an autoimmune condition where the immune system damages insulin-producing cells. While more extensive studies are required to see how long the benefits of the treatment can last, the new therapy developed by Boston-based Vertex Pharmaceuticals provides strong evidence that it's possible to replace the body's lost insulin production using infusions of stem cells. Related: People with type 1 diabetes are dependent on a precarious balance of insulin therapy for their whole lives. If their insulin drops too low, cells are unable to make use of the sugar in their bloodstream, leading to a buildup that can damage organs. If insulin is too high, patients are plunged into hypoglycemia, which can result in a loss of consciousness, seizures, coma, or death. The pancreas's islet cells are responsible for maintaining most of our bodies' insulin levels. Donor transplants of healthy versions of these cells have shown promise in treating type 1 diabetes in the past, but multiple donors are required, and donors are rare. So University of Toronto surgeon Trevor Reichman and colleagues infused 12 patients with islet cells derived from human stem cells in a treatment known as zimislecel. The patients also received immunosuppressive treatment before and after their zimislecel infusion. The islets not only produced insulin inside their bodies, but they did so at safe levels, reducing the patients' dependence on costly doses of insulin. "These findings showed that zimislecel islet cells were functional and self-regulated appropriately," the researchers write in their paper. The mild to moderate side-effects, including decreased kidney function and the anticipated drop in immune cells, were all linked with the immunosuppressive therapy. Sadly, two additional participants died during the trial; one from an infection arising from surgery and the other from complications due to an unrelated condition. As there were no serious adverse events attributed to the new islet cell therapy, the clinical trials are have progressed into phase 3. "These findings provide evidence that pancreatic islets can be effectively produced from pluripotent stem cells and used to treat type 1 diabetes," Reichman and team conclude. This research was published in NEJM. Scientists Identify New Blood Group, And It's The World's Rarest Extreme Heat Wave Scorches The US: Here's How You Can Stay Safe Your Brain Has a Hidden Rhythm, And It May Reveal How Smart You Are
UPI
an hour ago
- UPI
Space X set to launch Transporter-14 rideshare mission
SpaceX is set to launch its Transporter-14 rideshare mission that will carry dozens of payloads, including multiple satellites and human DNA. File Photo by Joe Marino/UPI | License Photo June 23 (UPI) -- SpaceX is set to launch its Transporter-14 rideshare mission, carrying multiple satellites and human DNA. The flight is set to launch from California's Vandenberg Space Force Base with a 57-minute flight window set to open at 5:18 p.m. EDT. The flight is set to carry 70 payloads, including cubesats, microsats and re-entry capsules. A German Company, Exolaunch, will also deploy a payload carrying 45 satellites of deployment hardware on this flight, its largest ever deployment including a satellite that is used to study water quality from space, and a Earth observation satellite will be used to look over cloudy conditions. Exolaunch CEO Robert Sproles said that SpaceX's rideshare program is "industry enabling". "It gives an opportunity to really pressure test not only our hardware, but all of our systems and missions management to make this a very smooth process for our customers so that they have a really easy time," Sproles said. Celetsis, a Houston-based company behind space-burial services, announced the flight would also have a payload that is carrying over 150 flight capsules with DNA and human remains. The payload from Celetsis will reach low Earth orbit and did two or three circuits around before re-entering the atmosphere. The capsules were then recovered from the Pacific Ocean and returned to the clients. "Celestis is pleased to offer a new type of Earth Rise mission, thanks to The Exploration Company," the company's co-founder and CEO Charles Chafer, said in a statement. "Our participants' capsules will orbit the Earth and return via the Mission Possible capsule, creating a spectacular liftoff and recovery experience." Transporter was initially set to launch on Sunday but was scrubbed due to unfavorable weather.
Medscape
an hour ago
- Medscape
Should CV Risk Equations Add Lp(a)?
Whether to measure Lp(a), a lipoprotein associated with increased cardiovascular risk, and how to use that information in risk assessment is a hot topic in cardiovascular medicine. The American Heart Association recently introduced the Predicting Risk of Cardiovascular EVENT (PREVENT) equations — an update to the pooled cohort equations. Neither risk calculator includes values for Lp(a). A recent study looked at whether adding Lp(a) to the PREVENT equations would improve risk prediction. It found that including the lipid parameter yielded a modest improvement at a population level but appeared to be more useful for personalized risk assessment, particularly among lower-risk individuals. 'Our results validate the PREVENT equations on a population level and show that they perform well, both in people with and without high levels of Lp(a),' lead author of the study, Harpreet Bhatia, MD, University of California San Diego, told Medscape Medical News . 'While I think our results would not support adding Lp(a) to the PREVENT equations, they confirm that on an individual-patient basis Lp(a) can add information,' he commented. Bhatia explained that the PREVENT risk equations are going to be the future paradigm of risk stratification in the primary prevention setting in the US, eventually replacing the pooled cohort equations which have been used for many years. The reason that Lp(a) wasn't included in either risk score, he suspects is because the datasets on which the risk equations are based would not have these values available. The PREVENT equations removed the consideration of race or ethnicity, as there is now acknowledgement that race is more of a social construct, but it is known that Lp(a) levels vary by ancestry, he said. Bhatia believes that Lp(a) should be routinely tested at least once in all adults; 'For those of us who practice preventive cardiology and lipidology, it can alter our clinical management.' Current American Heart Association/ American College of Cardiology cholesterol guidelines from 2018 do not recommend universal testing of Lp(a) but include it as a risk enhancing factor; updated guidelines are expected within the next year. Guidelines from the European Society of Cardiology and Canada and the US National Lipid Association do recommend measuring Lp(a). For the current study, Bhatia and colleagues examined data from the Multi-Ethnic Study of Atherosclerosis, a US study of 6670 people started in the year 2000, and the UK Biobank, a study of over 500,000 individuals from the UK started around 2006. Participants had no known cardiovascular disease at baseline and most had an Lp(a) measurement. Bhatia noted that his study used risk thresholds established for the pooled cohort equations, but it has not yet been decided what the cut points will be for the PREVENT equations. Low risk was defined as < 5%; borderline as 5%-7.5%; intermediate as 7.5%-20%, and high as ≥ 20% predicted 10-year risk for cardiovascular disease. 'PREVENT Equations Generally Do A Good Job' 'Essentially, what we saw was that the PREVENT equations generally do a good job of putting people into those 10-year risk categories across the board,' Bhatia said. However, they also found that within each category and across the board, if Lp(a) was high, then the cardiovascular risk was increased compared to individuals with a lower Lp(a) and sometimes quite significantly increased. The researchers also tried to establish whether Lp(a) could improve risk prediction on top of the PREVENT equations, using the Net Reclassification Index (NRI) which looks at the percentage of people who would be reclassified based on the new model (the proportion who move up minus the proportion who move down). They found that Lp(a) levels led to a modest improvement in risk prediction according to the NRI. In terms of atherosclerotic cardiovascular disease (ASCVD), including elevated Lp(a) on top of the PREVENT equations appropriately reclassified about 6% of people. With regard to coronary artery disease, which Lp(a) is most strongly associated with, the NRI was about 8%. Another measure of how well a new model predicts risk — the C index — found that the addition of Lp(a) did not significantly modify results. 'Our results suggest there does seem to be some improvement in risk prediction with Lp(a) for some individuals, particularly those at lower cardiovascular risk,' Bhattia said, an observation he described as 'intriguing'. He does not believe that new equations are needed that incorporate Lp(a). He pointed out that statin therapy for prevention is more strongly recommended in intermediate/higher risk patients, with a weaker recommendation for those at lower risk when there's the presence of an additional risk enhancing factor. 'It may be that someone at low risk in the equations with an elevated Lp(a) may be eligible for starting statins.' Bhatia already considers Lp(a) levels in this way in his clinic. He said that Lp(a) testing is simple and widely available, and the majority of people will only need to be tested once in their lifetime. He explained that most people who have low or high levels would stay in those categories long term, while people who have intermediate or borderline levels (30-50 mg/dL or 75-125 nmol/L) may need repeat testing if something changes that can affect Lp(a) levels longer term such as going through menopause, or the development of kidney or thyroid disease. Lp(a) Testing Worthwhile In an editorial accompanying the publication, Donald M. Lloyd-Jones, MD, Framingham Center for Population and Prevention Science, Boston University, Framingham, Massachusetts, and Amit Khera, MD, University of Texas Southwestern Medical School, Dallas, said the results are a useful validation of the PREVENT risk equations in contemporary broad populations and large real-world clinical samples. In terms of whether Lp(a) should be incorporated directly as a variable in the PREVENT equations, the editorialists have a similar view to Bhatia. 'That appears unnecessary,' they wrote. But, like Bhatia, they believe that Lp(a) should be measured once in everyone to help understand and individualize risk. 'Lp(a) is indeed a risk-enhancing, likely causal, factor for ASCVD. Its absence does not exonerate traditional risk factors, but its presence can amplify and personalize that risk, and help guide clinicians and patients regarding use and intensity of preventive therapies,' they concluded. Also commenting on this latest study, was Nathan Wong, PhD, from the University of California Irvine School of Medicine. He told Medscape Medical News that the analysis shows that the PREVENT risk score predicts ASCVD outcomes similarly in those with and without elevated Lp(a) levels. The stronger prediction of Lp(a) in lower risk people 'argues for the need to promote increased screening in the broader population, including those at lower risk' he said noting that most recommendations in the past have focused on people at higher risk such as those with a personal history of ASCVD. Wong agreed with Bhatia that the value of Lp(a) is more at the individual level than at the population wide level. But he does believe a risk score incorporating Lp(a) could be helpful for personalizing treatment strategies in certain individual patients, particularly for those with elevated Lp(a) levels who may not already be identified as high risk. Indeed, Wong and colleagues recently published such a score and showed that incorporating Lp(a) into ASCVD risk prediction models developed using a real-world clinic population moderately improves performance over 10 years, with good generalizability when applied to other US population cohorts. In that paper, a 25 mg/dL increment in Lp(a) was associated with a 23% increased risk for incident ASCVD. Levels ≥ 75 mg/dL conferred a near two-fold greater risk for ASCVD, including a 2.5-fold greater risk for stroke compared with Lp(a) levels < 25 mg/dL. They also demonstrated that adding Lp(a) to the pooled cohort equations ASCVD risk calculator correctly reclassified 45% of borderline-intermediate risk patients who experienced incident ASCVD as high-risk. However, about 24% who did not experience events were incorrectly reclassified high-risk (for an NRI of 21%). He cited a use case of a Black man aged 65 years with an Lp(a) of 80 mg/dL and a 10-year ASCVD risk of 18% without considering Lp(a) who would be up-stratified to 24% after factoring in Lp(a). 'Based on current guidelines, this person would now be clearly recommended for a statin to lower his ASCVD risk which may not have been as certain based on the risk not incorporating Lp(a),' he said. Recent studies have also shown identification of elevated Lp(a) levels can result in greater use of lipid-lowering therapy, he added. Wong also agreed with Bhatia on the distinction between risk prediction in populations vs individuals. 'We don't practice medicine on populations. We practice it on individuals and for certain individuals a risk score that incorporates Lp(a) can reclassify their risk category significantly dependent on how high their Lp(a) is,' he stated.
